FORMULATION AND IN VITRO–IN VIVO PHARMACOKINETIC EVALUATION OF CARDIOVASCULAR DRUG-LOADED PULSATILE DRUG DELIVERY SYSTEMS

Objective: This study is to formulate Nebivolol into a Pulsatile liquid, solid composite compression coated tablet, which will delay the release of drug in early morning hypertension conditions. Methods: The tablet was formulated and compressed with ethylcellulose coating polymer. percent vitro liquid tested. Based on disintegration time wetting time, LCS2, LCS3, LSC6, LCS7 LCS12 formulations were found be optimized solid-liquid compacts fast-dissolving core formulations, may excellent candidates for further polymer transfer press pulsatile formulations. Coating varying ethyl cellulose concentrations resulted five different press-coated (CT1, CT2, CT3, CT4, CT5). In release, kinetic studies, vivo pharmacokinetic stability tests all performed prepared tablet. Results: CT3 tablets are polymer, shows maximum controlled from i.e. 96.34±1.2% at 8th h. It there an efficient form up 3 h, followed by amount 96.34±2.4 8h. Which more efficiently protected gastric acid environment 1.2 pH, duodenal 4.0 pH only small intestine. Conclusion: According findings, increased bioavailability 3.11 percent.